Toggle Main Menu Toggle Search

Open Access padlockePrints

Sentinel Node in Oral Cancer The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial

Lookup NU author(s): Professor Philip Sloan

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Purpose: Nuclear imaging plays a crucial role in lymphatic mapping of oral cancer. This evaluation represents a subanalysis of the original multicenter SENT trial data set, involving 434 patientswith T1-T2, N0, and M0 oral squamous cell carcinoma. The impact of acquisition techniques, tracer injection timing relative to surgery, and causes of false-negative rate were assessed.Methods: Three to 24 hours before surgery, all patients received a dose of Tc-99m-nanocolloid (10-175 MBq), followed by lymphoscintigraphy. According to institutional protocols, all patients underwent preoperative dynamic/static scan and/or SPECT/CT.Results: Lymphoscintigraphy identified 723 lymphatic basins. 1398 sentinel lymph nodes (SNs) were biopsied (3.2 SN per patient; range, 1-10). Dynamic scan allowed the differentiation of sentinel nodes from second tier lymph nodes. SPECT/CT allowed more accurate anatomical localization and estimated SN depth more efficiently. After pathological examination, 9.9% of the SN excised (138 of 1398 SNs) showed metastases. The first neck level (NL) containing SN+ was NL I in 28.6%, NL IIa in 44.8%, NL IIb in 2.8%, NL III in 17.1%, and NL IV in 6.7% of positive patients. Approximately 96% of positive SNs were localized in the first and second lymphatic basin visualized using lymphoscintigraphy. After neck dissection, the SN+ was the only lymph node containing metastasis in approximately 80% of patients.Conclusions: Best results were observed using a dynamic scan in combination with SPECT/CT. A shorter interval between tracer injection, imaging, and surgery resulted in a lower false-negative rate. At least 2 NLs have to be harvested, as this may increase the detection of lymphatic metastases.


Publication metadata

Author(s): Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MFF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Gutierrez LMJ, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M

Publication type: Article

Publication status: Published

Journal: Clinical Nuclear Medicine

Year: 2016

Volume: 41

Issue: 7

Pages: 534-542

Print publication date: 01/07/2016

Acceptance date: 01/01/1900

ISSN (print): 0363-9762

ISSN (electronic): 1536-0229

Publisher: Lippincott Williams & Wilkins, Ltd.

URL: http://dx.doi.org/10.1097/RLU.0000000000001241

DOI: 10.1097/RLU.0000000000001241


Altmetrics

Altmetrics provided by Altmetric


Share